Preliminary studies reveal that NRP-1 and NRP-2 inhibitors can efficiently limit angiogenesis and reduce the tumor’s potential to metastasize, making them promising therapeutic targets [19,21]. This evidence concerns the gene NRP1 and neoplasm.